{"product_id":"aort-vrio-analysis","title":"Artivion, Inc. (AORT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eDiscover the true engine behind Artivion, Inc. (AORT)'s market performance! This VRIO analysis distills whether its core assets possess the necessary Value, Rarity, Inimitability, and Organization to secure a lasting competitive advantage. Click below to see the definitive assessment of what truly makes Artivion, Inc. (AORT) irreplaceable.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eArtivion, Inc. (AORT) - VRIO Analysis: 1. On-X Mechanical Heart Valve Franchise\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at Artivion, Inc.'s crown jewel, the On-X Mechanical Heart Valve, to see how durable its competitive edge really is. Based on the latest numbers, this franchise is definitely a sustained advantage, but it requires continuous investment to keep it that way.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Yes. This franchise is a massive revenue driver. In the third quarter of fiscal 2025, On-X revenue grew 23% year-over-year on a constant currency basis, contributing significantly to the company's total revenue of $113.4 million for the quarter. It's valued because it's the only mechanical aortic valve approved for patients needing a lower anticoagulation level.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Yes. While mechanical valves are common, the On-X design is rare because it is the only one with FDA, Health Canada, and CE Mark approval for a Low INR of 1.5 – 2.0. This low INR setting is clinically proven to result in an 87% reduction in major bleeding events compared to the standard INR of 2.0-3.0.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult. Competitors can't just copy the design; they have to replicate the years of clinical history supporting the low INR claim and build the same level of surgeon confidence. That takes time and massive investment in post-market studies, which Artivion has already done. It’s not impossible, but it’s a high barrier to entry.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. Artivion is actively organizing to support this growth. They recently purchased two facilities in Austin, Texas, on September 26, 2025, to expand On-X manufacturing capacity, spending $20.5 million cash for approximately 162,000 square feet of combined manufacturing and office space. This shows they are putting capital behind the product's success.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The combination of proven clinical superiority (low bleeding risk) and the organizational commitment (facility expansion) creates a durable moat. Competitors face a steep climb to match both the clinical data and the production scale.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment for this key asset:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eImplication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eExploits market opportunity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eUnique clinical profile (Low INR)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eHigh clinical data\/surgeon trust barrier\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eRecent capital investment in Austin capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003eDurable market position\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the risk from the broader pipeline; while On-X is strong, Artivion is also banking on the AMDS launch, which saw 31% constant currency growth in Q3 2025. Still, the On-X franchise provides the necessary stability.\u003c\/p\u003e\n\n\u003cp\u003eKey supporting facts for the On-X franchise:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 On-X revenue growth: 23% constant currency.\u003c\/li\u003e\n\u003cli\u003eUnique approval: Only mechanical valve for low INR of 1.5 – 2.0.\u003c\/li\u003e\n\u003cli\u003eBleeding risk reduction: 87% lower major bleeding risk.\u003c\/li\u003e\n\u003cli\u003eManufacturing expansion: $20.5 million spent on Austin, Texas facilities in late September 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: update the 2026 capital expenditure plan to reflect the full integration cost of the new Austin facilities by next Tuesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eArtivion, Inc. (AORT) - VRIO Analysis: 2. AMDS Technology \u0026amp; Clinical Validation\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e A key growth engine, with stent graft revenues up \u003cstrong\u003e31%\u003c\/strong\u003e year-over-year on a constant currency basis in Q3 2025. Total company constant currency revenue growth for Q3 2025 was \u003cstrong\u003e16%\u003c\/strong\u003e. It addresses complex aortic arch repair.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Other endovascular solutions exist, but AMDS has favorable, recently presented clinical data from PERSEVERE and PROTECT trials. The PERSEVERE clinical trial underpinning the AMDS Premarket Approval (PMA) met its primary endpoints.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eClinical Endpoint\/Metric\u003c\/th\u003e\n\u003cth\u003ePERSEVERE Trial Result (30-Day)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVisceral Malperfusion Resolution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e83%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenal Malperfusion Resolution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReduction in All-Cause Mortality (vs. Hemiarch)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e72%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReduction in Primary Major Adverse Events (MAEs) (vs. Hemiarch)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e54%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistal Anastomotic New Entry (DANE) Tears Occurrence\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eZero\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnical Success Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e98.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. Competitors will try to match the data, but the HDE status and initial adoption curve offer a lead. AMDS is available in the United States under a Humanitarian Device Exemption (HDE).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe HDE allows for commercial distribution in the U.S. prior to anticipated PMA approval.\u003c\/li\u003e\n\u003cli\u003eThe HDE covers acute DeBakey type I dissections in the presence of malperfusion, representing approximately \u003cstrong\u003e40%\u003c\/strong\u003e of all acute DeBakey type I dissections in the U.S.\u003c\/li\u003e\n\u003cli\u003eThe potential US market for the full PMA approval (with and without malperfusion) is estimated at \u003cstrong\u003e$150 million\u003c\/strong\u003e annually.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. Management is actively pushing for PMA approval and secured a favorable reimbursement code (MSDRG DRG-209) effective \u003cstrong\u003eOctober 1, 2025\u003c\/strong\u003e. Gross margins reached \u003cstrong\u003e65.6%\u003c\/strong\u003e in Q3 2025, up from \u003cstrong\u003e63.7%\u003c\/strong\u003e a year ago, partly attributed to favorable mix from AMDS HDE revenues.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eThree of four modules\u003c\/strong\u003e have been filed for the AMDS PMA.\u003c\/li\u003e\n\u003cli\u003ePMA approval was previously expected in late \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe new reimbursement code, MSDRG DRG-209 (Complex Arch Procedures), reflects a meaningful increase to reimbursement for these procedures.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The current lead from data and reimbursement is strong but not permanent.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eArtivion, Inc. (AORT) - VRIO Analysis: 3. High-Margin Product Mix \u0026amp; Gross Margin Expansion\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly translates top-line growth into disproportionately higher profit.\u003c\/p\u003e\n\u003cp\u003eQ3 2025 gross margin reached \u003cstrong\u003e65.6%\u003c\/strong\u003e, an increase of \u003cstrong\u003e200 basis points\u003c\/strong\u003e from \u003cstrong\u003e63.7%\u003c\/strong\u003e in Q3 2024. This expansion is attributed to the favorable mix from \u003cstrong\u003eAMDS HDE revenues\u003c\/strong\u003e and strong \u003cstrong\u003eOn-X\u003c\/strong\u003e performance. The \u003cstrong\u003eAMDS\u003c\/strong\u003e segment represents a significant future high-margin opportunity, cited as a \u003cstrong\u003e$150 million\u003c\/strong\u003e annual market opportunity.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Value\u003c\/th\u003e\n\u003cth\u003eYoY Growth (Q3 2025 vs Q3 2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e65.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e200 basis points\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStent Grafts Revenue (GAAP)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e38%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-X Revenue (GAAP)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e25%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (GAAP)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$113.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e18%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e39%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many med-tech firms target high margins, but Artivion is successfully executing the shift now.\u003c\/p\u003e\n\u003cp\u003eSuccessful execution is evidenced by the product segment growth driving margin expansion:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eStent grafts revenue grew \u003cstrong\u003e38%\u003c\/strong\u003e (GAAP) in Q3 2025 year-over-year.\u003c\/li\u003e\n\u003cli\u003eOn-X revenue grew \u003cstrong\u003e25%\u003c\/strong\u003e (GAAP) in Q3 2025 year-over-year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary. Competitors can develop high-margin products, but Artivion is capturing the value first.\u003c\/p\u003e\n\u003cp\u003eArtivion is currently realizing the financial benefits of its high-margin product adoption ahead of potential competitive entry.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The financial strategy explicitly centers on leveraging high-margin products to achieve EBITDA growth at twice the revenue rate.\u003c\/p\u003e\n\u003cp\u003eThe financial results demonstrate this leverage:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Adjusted EBITDA growth was \u003cstrong\u003e39%\u003c\/strong\u003e, significantly outpacing the \u003cstrong\u003e18%\u003c\/strong\u003e GAAP revenue growth (or \u003cstrong\u003e16%\u003c\/strong\u003e constant currency revenue growth).\u003c\/li\u003e\n\u003cli\u003eFull Year 2025 Adjusted EBITDA guidance growth is projected to be between \u003cstrong\u003e24%\u003c\/strong\u003e and \u003cstrong\u003e28%\u003c\/strong\u003e over 2024.\u003c\/li\u003e\n\u003cli\u003eManagement expects Adjusted EBITDA to \u003cstrong\u003eoutpace revenue\u003c\/strong\u003e growth in 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Success depends on maintaining the pipeline of high-margin launches.\u003c\/p\u003e\n\u003cp\u003eThe continued advantage is tied to pipeline execution, with the company raising its full-year 2025 revenue guidance to a range of \u003cstrong\u003e$439 to $445 million\u003c\/strong\u003e (reported revenue).\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eArtivion, Inc. (AORT) - VRIO Analysis: 4. Pivotal Clinical Pipeline Execution\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Ensures future revenue streams by advancing next-generation devices like Arcevo LSA and NEXUS. The ARTIZEN trial for Arcevo LSA has treated its first patient in November 2025, with a potential U.S. market opening as soon as \u003cstrong\u003e$80 million\u003c\/strong\u003e by \u003cstrong\u003e2029\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many companies have pipelines, but Artivion is successfully enrolling pivotal trials and presenting late-breaking science, such as the 63% reduction in MAE rate from the NEXUS TRIOMPHE trial data presented at AATS in May 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Successfully navigating complex, multi-year pivotal trials requires deep regulatory and clinical expertise, evidenced by the progression of multiple devices.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The company is clearly organized around this, with management highlighting pipeline progress as a key catalyst, reflected in the FY25 Adjusted EBITDA guidance of $88M to $91M, representing 24-28% year-over-year growth.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A consistent ability to bring new, differentiated technologies through the regulatory gauntlet is hard to copy, supported by the Q3 2025 revenue growth of 16% constant currency.\u003c\/p\u003e\n\u003cp\u003eThe execution across the pipeline is quantified by the following key milestones and trial metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePipeline Asset\u003c\/th\u003e\n\u003cth\u003eU.S. Trial Status\u003c\/th\u003e\n\u003cth\u003eKey Endpoint\/Data Point\u003c\/th\u003e\n\u003cth\u003eEstimated U.S. TAM\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eArcevo LSA\u003c\/td\u003e\n\u003ctd\u003eARTIZEN Pivotal Trial Initiated (Nov 2025)\u003c\/td\u003e\n\u003ctd\u003ePrimary endpoint includes reduction in all-cause mortality, stroke, paraplegia\/paraparesis\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$80 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNEXUS\u003c\/td\u003e\n\u003ctd\u003eTRIOMPHE IDE Enrollment Completed (as of Q3 2024)\u003c\/td\u003e\n\u003ctd\u003eShowed 63% reduction in MAE rate at 30 days\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$150 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMDS Hybrid Prosthesis\u003c\/td\u003e\n\u003ctd\u003eFirst PMA Module Submitted (as of Q3 2024)\u003c\/td\u003e\n\u003ctd\u003ePERSEVERE trial for acute DeBakey Type I aortic dissections\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$150 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific details regarding the ongoing pivotal trials include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe ARTIZEN trial for Arcevo LSA is a prospective, multicenter, non-randomized clinical trial consisting of 132 participants in the U.S. and Europe at up to 30 centers.\u003c\/li\u003e\n\u003cli\u003eThe NEXUS TRIOMPHE IDE Study is a multi-arm, multi-center study aiming to enroll up to 110 patients across 31 sites.\u003c\/li\u003e\n\u003cli\u003eThe Endospan NEXUS device addresses an estimated $600 million global market opportunity.\u003c\/li\u003e\n\u003cli\u003eThe company's overall financial performance supports pipeline investment, with Q3 2025 Adjusted EBITDA reaching $24.6 million, a 39% increase year-over-year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eArtivion, Inc. (AORT) - VRIO Analysis: 5. Strategic Financial Deleveraging\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Improves balance sheet flexibility and reduces risk; net leverage dropped to \u003cstrong\u003e1.8\u003c\/strong\u003e as of September 30, 2025, from \u003cstrong\u003e3.9\u003c\/strong\u003e a year prior. They retired \u003cstrong\u003e$100 million\u003c\/strong\u003e in debt.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many peers carry higher leverage; this proactive move is a differentiator in late 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Requires disciplined capital allocation and market timing to execute large debt retirements effectively.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The CFO explicitly reported on the debt conversion and leverage improvement as a strategic step.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. The current low leverage is a result of specific past actions; maintaining it requires ongoing discipline.\u003c\/p\u003e\n\n\u003cp\u003eThe strategic financial deleveraging is evidenced by the following key metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet Leverage Ratio as of September 30, 2025: \u003cstrong\u003e1.8\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Leverage Ratio as of September 30, 2024 (one year prior): \u003cstrong\u003e3.9\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDebt Retired (as per strategic goal): \u003cstrong\u003e$100 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash on Hand as of September 30, 2025: \u003cstrong\u003e$73.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Debt as of September 30, 2025: \u003cstrong\u003e$214.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFinancial Maintenance Covenant (effective Q1 2025 onwards): Total net leverage ratio not greater than \u003cstrong\u003e5.75x\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNew Credit Facility Secured: \u003cstrong\u003e$150 million\u003c\/strong\u003e loan facility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eComparative Financial Position Data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue as of September 30, 2025\u003c\/th\u003e\n\u003cth\u003eValue as of December 31, 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Leverage Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A (Covenant $\\le 5.75\\text{x}$)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt (Millions USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$214.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$362.258\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (Millions USD)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$73.4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey Financial Context Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Total Revenues: \u003cstrong\u003e$113.4 million\u003c\/strong\u003e, an \u003cstrong\u003e18%\u003c\/strong\u003e increase GAAP basis year-over-year.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Adjusted EBITDA: \u003cstrong\u003e$24.6 million\u003c\/strong\u003e, a \u003cstrong\u003e39%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eFull Year 2025 Adjusted EBITDA Guidance Midpoint: Expected range of \u003cstrong\u003e$88 million\u003c\/strong\u003e to \u003cstrong\u003e$91 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eArtivion, Inc. (AORT) - VRIO Analysis: 6. Focused Aortic Disease Market Specialization\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for deep expertise, targeted R\u0026amp;D, and efficient sales force deployment, focusing on a clear, aging-population-driven market need. The Total Addressable Market (TAM) for aortic disease is estimated to exceed $5.3 billion. The company's pipeline products are projected to unlock approximately $1 billion of incremental market opportunity over the next five-plus years.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While competitors exist, Artivion has explicitly focused on aortic technologies and divesting non-aortic assets. The company has made strategic acquisitions to bolster this focus, such as the 2016 acquisition of On-X Life Technologies for $130 million and the 2017 acquisition of JOTEC GmbH for €225 million. Evidence of non-core divestiture includes the sale of the PerClot product line, resulting in a $14.3 million gain in 2023.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Building two decades of deep, focused clinical and procedural knowledge in one complex area is not easily replicated. The company dedicates approximately 7% to 8% of revenue to Research and Development, targeting new high-margin aortic technologies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The entire corporate strategy is anchored on this focus, driving product development and M\u0026amp;A decisions. The company employs 1,600+ global employees dedicated to this mission.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Deep specialization in a complex field builds organizational knowledge that is slow to imitate.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Range\u003c\/th\u003e\n\u003cth\u003eYear\/Period\u003c\/th\u003e\n\u003cth\u003eSource of Focus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Addressable Market (TAM)\u003c\/td\u003e\n\u003ctd\u003eOver $5.3 billion\u003c\/td\u003e\n\u003ctd\u003eCurrent\/Ongoing\u003c\/td\u003e\n\u003ctd\u003eAortic Disease Market Size\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Incremental Opportunity\u003c\/td\u003e\n\u003ctd\u003eApproximately $1 billion\u003c\/td\u003e\n\u003ctd\u003eNext five-plus years\u003c\/td\u003e\n\u003ctd\u003eNew PMA products like Arcevo LSA and NEXUS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D as % of Revenue\u003c\/td\u003e\n\u003ctd\u003e7% to 8%\u003c\/td\u003e\n\u003ctd\u003eCurrent Guidance\u003c\/td\u003e\n\u003ctd\u003eTargeting new high-margin aortic technologies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Gross Margin\u003c\/td\u003e\n\u003ctd\u003e65%\u003c\/td\u003e\n\u003ctd\u003eCurrent Average\u003c\/td\u003e\n\u003ctd\u003eOverall portfolio margin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMDS Target Gross Margin\u003c\/td\u003e\n\u003ctd\u003eExceed 90%\u003c\/td\u003e\n\u003ctd\u003eFuture Product Mix\u003c\/td\u003e\n\u003ctd\u003eShift toward higher-margin devices\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Revenue Guidance (Midpoint)\u003c\/td\u003e\n\u003ctd\u003e$440 million\u003c\/td\u003e\n\u003ctd\u003eFull Year 2025\u003c\/td\u003e\n\u003ctd\u003eGuidance based on core business execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organizational structure supports this focus through dedicated segments and leadership review:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Chief Operating Decision Maker (CODM) reviews performance based on segment gross margin or net external revenues less cost of products and preservation services for the two reportable segments: Medical Devices and Preservation Services.\u003c\/li\u003e\n\u003cli\u003eThe Medical Devices segment includes aortic stent grafts, On-X products, and surgical sealants, all central to the aortic focus.\u003c\/li\u003e\n\u003cli\u003eThe company's vision is 'To be recognized as a leader in providing technologies for patients with aortic disease'.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eArtivion, Inc. (AORT) - VRIO Analysis: 7. Resolved and Expanded Manufacturing Footprint\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eEnsures product availability and quality, directly supporting the 16% constant currency revenue growth in Q3 2025. Total revenues for Q3 2025 were $113.4 million. They resolved prior cyberattack-related supply chain issues, with management confirming tissue processing volumes have 'normalized' following the disruption caused earlier in 2024.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerate. Recovering from a major cyber incident in 2024 while simultaneously expanding capacity (e.g., purchasing two facilities in Austin, Texas to support On-X production) is a strong operational feat.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eHigh. Rebuilding trust and capacity after a disruption, especially in regulated manufacturing, takes time and specific operational fixes. The successful Q3 2025 performance, including 39% Adjusted EBITDA growth year-over-year to $24.6 million, reflects this recovery.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eYes. Management confirmed normalization of tissue volumes and capacity expansion for key products. The company raised its full-year 2025 revenue guidance to a range of $439 to $445 million.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary. While recovery is complete, competitors can build new capacity faster if they haven't faced the same disruption. The 5% constant currency growth in preservation services (tissue processing) in Q3 2025 demonstrates the return to normalized output.\u003c\/p\u003e\n\u003cp\u003eThe manufacturing footprint resolution directly supported the following Q3 2025 revenue increases compared to Q3 2024:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct Line\u003c\/th\u003e\n\u003cth\u003eGAAP Revenue Growth\u003c\/th\u003e\n\u003cth\u003eConstant Currency (cc) Revenue Growth\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStent Grafts\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e38%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-X\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreservation Services\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioGlue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey operational and financial metrics reflecting manufacturing stability and output in Q3 2025 include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross Margin: \u003cstrong\u003e65.6%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA Margin: \u003cstrong\u003e21.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Income: \u003cstrong\u003e$6.5 million\u003c\/strong\u003e, compared to a net loss of \u003cstrong\u003e$(2.3) million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eFull Year 2025 Adjusted EBITDA Guidance Raised to a range of \u003cstrong\u003e$88 to $91 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Leverage Ratio: \u003cstrong\u003e1.8x\u003c\/strong\u003e as of September 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eArtivion, Inc. (AORT) - VRIO Analysis: 8. Favorable Reimbursement Access for New Tech\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Accelerates adoption and improves hospital economics for new devices like AMDS. The new MSDRG DRG-209 code provides a meaningful reimbursement increase.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe favorable reimbursement environment is supported by the clinical superiority of the AMDS device and the subsequent creation of a dedicated payment mechanism.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAMDS Clinical\/Market Data Point\u003c\/td\u003e\n\u003ctd\u003eValue\/Amount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS Market Opportunity (Full PMA)\u003c\/td\u003e\n\u003ctd\u003eEstimated Annual US Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$150 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Market Opportunity\u003c\/td\u003e\n\u003ctd\u003eEstimated Annual Global Patients \/ Market Size\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48,000\u003c\/strong\u003e patients \/ \u003cstrong\u003e$540 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHDE Initial Addressable Market\u003c\/td\u003e\n\u003ctd\u003ePercentage of US Acute DeBakey Type I Dissections Covered\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAll-Cause Mortality Reduction (30-Day vs. Standard Care)\u003c\/td\u003e\n\u003ctd\u003ePERSEVERE Trial Endpoint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e72%\u003c\/strong\u003e reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Major Adverse Events (MAE) Reduction (30-Day vs. Standard Care)\u003c\/td\u003e\n\u003ctd\u003ePERSEVERE Trial Endpoint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e54%\u003c\/strong\u003e reduction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistal Anastomotic New Entry (DANE) Occurrence\u003c\/td\u003e\n\u003ctd\u003eAMDS vs. Standard Care Hemiarch Repair\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eZero\u003c\/strong\u003e occurrence vs. \u003cstrong\u003e45%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Gaining a new, favorable DRG code for a complex procedure is a significant, non-replicable win for that specific technology.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCMS proposed the creation of a new base MS-DRG, \u003cstrong\u003e209\u003c\/strong\u003e (Complex Aortic Arch Procedures), to account for greater clinical resources.\u003c\/li\u003e\n\u003cli\u003eThe AMDS Hybrid Prosthesis received Humanitarian Device Exemption (HDE) designation, being the world's \u003cstrong\u003efirst\u003c\/strong\u003e aortic arch remodeling device for this indication.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Competitors must go through the same lengthy process for their own novel devices.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe HDE was granted following full cohort data from the PERSEVERE US IDE trial, which consisted of \u003cstrong\u003e93\u003c\/strong\u003e participants in the U.S..\u003c\/li\u003e\n\u003cli\u003eFull Premarket Approval (PMA) for the entire US market is anticipated in late \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Management actively cited this code as a driver for AMDS adoption momentum.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCEO Pat Mackin stated the new \u003cstrong\u003eDRG-209\u003c\/strong\u003e update should act as a tailwind by reducing hospital cost constraints.\u003c\/li\u003e\n\u003cli\u003eManagement cited positive new clinical data and \u003cstrong\u003eincremental reimbursement improvements\u003c\/strong\u003e for complex aortic procedures as supporting the value proposition.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary. This advantage is tied to the AMDS product's current lifecycle stage.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe immediate advantage is tied to the HDE allowing commercial distribution for approximately \u003cstrong\u003e40%\u003c\/strong\u003e of acute DeBakey Type I dissections in the U.S..\u003c\/li\u003e\n\u003cli\u003eThis advantage is time-bound until the full PMA is approved, expected in late \u003cstrong\u003e2025\u003c\/strong\u003e, which would expand coverage to the full estimated \u003cstrong\u003e$150 million\u003c\/strong\u003e US market opportunity.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eArtivion, Inc. (AORT) - VRIO Analysis: 9. Established Global Commercial Presence\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides immediate access to international markets, with Q3 2025 revenue showing growth across North America ($\\mathbf{19\\%}$), Asia Pacific ($\\mathbf{18\\%}$), and EMEA ($\\mathbf{12\\%}$). Total Q3 2025 revenue was $\\mathbf{\\$113.4}$ million, representing a $\\mathbf{16\\%}$ year-over-year increase in constant currency.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low. Most established med-tech firms have global reach, but Artivion's is specifically tailored to its niche.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Building out international distribution networks, regulatory clearances, and local sales teams is capital-intensive and slow.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Yes. The consistent regional revenue growth demonstrates the organization is effectively managing its global footprint.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The established infrastructure is a sunk cost that new entrants cannot easily overcome.\u003c\/p\u003e\n\u003cp\u003eArtivion markets and sells its products in over $\\mathbf{100}$ countries. The operational structure supporting this presence includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDirect sales forces in the US and Canada.\u003c\/li\u003e\n\u003cli\u003eIndependent distributors and subsidiaries across EMEA, APAC, and LATAM regions.\u003c\/li\u003e\n\u003cli\u003eManufacturing centers strategically located in Kennesaw, Georgia; Austin, Texas; and Hechingen, Germany.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe regional revenue performance for Q3 2025 highlights the effectiveness of this global structure:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRegion\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Revenue Growth (Year-over-Year)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNorth America\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia Pacific\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEMEA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLatin America\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther context on international growth from Q1 2025 constant currency performance shows:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLatin America constant currency revenue growth: $\\mathbf{26\\%}$.\u003c\/li\u003e\n\u003cli\u003eEMEA constant currency revenue growth: $\\mathbf{14\\%}$.\u003c\/li\u003e\n\u003cli\u003eAsia-Pacific constant currency revenue growth: $\\mathbf{8\\%}$.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516113150101,"sku":"aort-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/aort-vrio-analysis.png?v=1740148513","url":"https:\/\/dcf-model.com\/es\/products\/aort-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}